20 / 25
Lenvatinib aprobado en Cáncer Renal Metastásico
20
Lenvima
®
approved by:
●FDA – USA (13th May 2016)
in combination with everolimus for patients with
advanced RCC following one prior anti-angiogenic therapy
.
Kisplyx
®
approved by:
●EMA - EU (25th Aug 2016)
in combination with everolimus for patients with
advanced RCC following one prior anti-angiogenic therapy
.